HOME >> BIOLOGY >> NEWS
'Cookbook recipes' would cure disease with nontoxic DNA delivery systems

CHAMPAIGN, Ill. -- Scientists studying the structure and interaction of negatively charged lipids and DNA molecules have created a "cookbook" for a class of nontoxic DNA delivery systems that will assist doctors and clinicians in the safe and effective delivery of genetic medicine.

As reported in the Aug. 9 issue of the Proceedings of the National Academy of Sciences, researchers have now performed a careful, comprehensive study to see how negatively charged lipids stick to negatively charged DNA and self-organize into structures.

"Many research groups have made concoctions with ingredients in different proportions and then assessed their effectiveness in gene delivery, but this is hard and requires a lot of intuition," said Gerard Wong, a professor of materials science and engineering, physics, and bioengineering at the University of Illinois at Urbana-Champaign, and corresponding author of the paper.

"By understanding some of the physics, we now have recipes for assembling delivery systems with different structures, which can have intrinsically different, controllable DNA delivery efficiencies," Wong said. "We found that the same family of structures are generated for many different ions."

Gene therapy is one of the most promising strategies for developing cures for many hereditary and acquired diseases. Protocols have been approved for treating cancer, cystic fibrosis and neuromuscular disorders, for example, but delivering DNA to the proper location and getting the right amount of DNA expression without killing innocent cells has become the Achilles' heel in DNA delivery.

Positively charged (cationic) synthetic molecules will readily bond to negatively charged DNA molecules and have been used for DNA delivery, but these cationic molecules are often toxic to cells, Wong said. An alternative is to use naturally occurring negatively charged (anionic) lipids that won't harm cells.

"The problem then becomes: 'How do you
'"/>

Contact: James E. Kloeppel, Physical Sciences Editor
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
10-Aug-2005


Page: 1 2

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. The bee that would be queen
3. Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
4. 2-protein team would be lost without each other
5. Healthy coastal wetlands would adapt to rising oceans
6. Is it ethical for scientists to do research abroad that would be forbidden at home?
7. Designer babies - what would you do for a healthy baby?
8. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
9. Proposal would allow wild animals to roam North America
10. Passage of Marin County GMO ban would encourage widespread use of harsh pesticides
11. Passage of GMO ban in San Luis Obispo would encourage use of harsh pesticides

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: